The definitive directory of precision medicine and molecular diagnostics companies, spanning liquid biopsy, genomic sequencing, precision oncology and digital pathology, minimal residual disease and early cancer detection, companion diagnostics, and rare disease genetic testing. Curated for biotech investors, pharma partners scouting companion diagnostics, and scientists tracking sequencing and liquid biopsy.
BioMed Nexus tracks 157 precision medicine and diagnostics companies across 7 categories: liquid biopsy, genomic & NGS, precision oncology, MRD & early detection, companion diagnostics, rare disease, and platform & data. The directory covers the leading diagnostics companies, including Illumina, Guardant Health, Foundation Medicine, Tempus AI, Natera and GRAIL, alongside emerging startups and featured partner 1Cell.Ai. Last updated August 2026
Precision oncology company reading DNA, RNA, and protein from single circulating tumor cells. Its cell biopsy® platform supports ADC target validation, clinical trial enrichment, and resistance monitoring, validated across 2,062 patient samples spanning more than nine cancer types.
Every listing here is free by name. Add a Verified Listing ($495 per year) with a tagline, website link, and verified badge, or go Featured for your logo, full description, and priority placement at the top of this directory. Data Partners also get a dedicated landing page and a sponsored spotlight in a daily brief reaching about 43,000 recipients.
Featured spots are limited per category.
1Cell.Ai has claimed the first featured spot. Every other company in this directory is still just a name in a database. Featured partners get a full profile with logo, assays, technology, backlinks, and priority placement at the very top of this page. Claim your spot before your competitors do. A Verified Listing is the lighter option: your tagline, website link, and verified badge for $495 per year.
The BioMed Nexus Precision Medicine & Diagnostics Directory is a comprehensive, regularly updated list of diagnostics and precision medicine companies, spanning liquid biopsy, genomic sequencing and NGS, precision oncology and digital pathology, minimal residual disease (MRD) and early cancer detection, companion diagnostics, rare disease genetic testing, and diagnostic data and analytics platforms. It covers established diagnostics leaders alongside emerging molecular and AI-driven startups, with featured partner profiles like 1Cell.Ai hosted on biomednexus.com.
Use it to research diagnostics companies by category, track the precision medicine landscape, and map testing and data partners. Whether you are a biotech investor evaluating molecular diagnostics, a pharma partner scouting companion diagnostic developers, or a scientist tracking sequencing and liquid biopsy, the directory provides structured, current company data. Curated and maintained by the BioMed Nexus editorial team; last updated August 2026.
Companies can claim a free listing by name or add a Verified Listing ($495 per year) with a tagline, website link, and verified badge. Featured Profiles and Data Partners get priority placement, and Data Partners add a dedicated landing page and a sponsored spotlight in the BioMed Nexus daily brief, which reaches about 43,000 recipients per weekday edition. Contact our partnerships team to learn more.
